Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial

Main Article Content

Mark Lebwohl
Icahn School of Medicine at Mount Sinai

Linda Stein Gold
Henry Ford Medical Center

Melinda J. Gooderham
SkiN Centre for Dermatology, Probity Medical Research and Queen’s University

Kim A. Papp
Probity Medical Research and K Papp Clinical Research

Laura K. Ferris
University of Pittsburgh

David N. Adam
CCA Medical Research, Probity Medical Research and Temerty Faculty of Medicine, University of Toronto

H. Chih-ho Hong
Probity Medical Research and University of British Columbia

Leon H. Kircik
Icahn School of Medicine at Mount Sinai, Indiana Medical Center, Physicians Skin Care, PLLC, and Skin Sciences, PLLC

Matthew Zirwas
Dermatologists of the Central States, Probity Medical Research, and Ohio University

Patrick Burnett
Arcutis Biotherapeutics, Inc.

Robert Higham
Arcutis Biotherapeutics, Inc.

Keywords

Plaque Psoriasis, roflumilast, phosphodiesterase 4 inhibitor

References

1. Dong C, et al. J Pharmacol Exp Ther2016;358:413–422.

2. Lebwohl MG, et al. N Engl J Med 2020;383:229–239.

3. Stein Gold LS, et al. Poster presented at: Innovations in Dermatology; March 16-20, 2021; Virtual.

Article Sidebar

Poster PDF
Published
Jul 17, 2023
DOI https://doi.org/10.25251/skin.7.supp.218

Article Details

How to Cite
Lebwohl, M., Stein Gold, L., Gooderham, M. J., Papp, K. A., Ferris, L. K., Adam, D. N., Hong, H. C.- ho, Kircik, L. H., Zirwas, M., Burnett, P., & Higham, R. (2023). Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial. SKIN The Journal of Cutaneous Medicine, 7(4), s218. https://doi.org/10.25251/skin.7.supp.218
Issue
Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23
Section
Posters from FC PANP 23 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 8 9 10 11 12 13 14 15 16 17 > >>